



THE CHINA CTAD

ADVANCED
WORKSHOP

AND COURSE IN AD CLINICAL TRIALS

September 6-7, 2025

Shanghai (China)

Partnership OPPORTUNITIES

Conference Venue: Hilton Shanghai Hongqiao
No. 1116, Hongsong East Road, Shanghai

JPAD
The Journal of Prevention of Alzheimer's Disease




TABLE OF CONTENT

Editorial	p.4
Advancing Alzheimer's Disease Research	p.5
Meeting participants	p.6
Partnership opportunities	p.7
Partnership levels and benefits	p.10

Contact

bene.clement@ant-congres.com
+33 6 10 25 38 96

Editorial

Dear Colleagues,

Since its inception in 2008, the Clinical Trials on Alzheimer's Disease (CTAD) conference has established itself as the premier global meeting exclusively dedicated to clinical trials in Alzheimer's Disease (AD) it is held annually at the end of the year either in Europe or in the USA.

We are pleased to announce a highly exclusive CTAD Workshop, taking place on September 6–7, 2025, in Shanghai, China.

This workshop will convene top leaders from China's foremost Alzheimer's research centers, alongside distinguished experts from Europe and the United States. It will serve as a platform to advance the CTAD Chinese Clinical Trials Centers Initiative and explore ways to collectively enhance clinical trial capabilities, accelerating the development of new therapeutic strategies for Alzheimer's Disease.

The program will feature focused discussions on critical topics, including:

- Newly approved therapies for Alzheimer's Disease and return on experience.
- Emerging diagnostic tools and biomarkers.
- Cutting-edge imaging technologies' impact in AD Clinical Trials.
- Exploring new avenues beyond amyloid-clearing treatments including:
 - Disease-modifying agents,
 - Gene therapy,
 - Vaccines
 - Lifestyle and multimodal interventions.
- Breakthrough translational research.
- Innovative therapeutic approaches.

In addition, the CTAD Conference invites abstract submissions from leading Chinese research teams to share their work within these categories, further enriching the exchange of groundbreaking ideas.

As this workshop is limited in attendance, participation will be reserved for a select group of distinguished experts. We hope you will join us in this pioneering initiative, which seeks to strengthen academic and industrial collaboration in Alzheimer's research. Together, we can make meaningful progress in the fight against this devastating disease, advancing the discovery of life-changing therapies and improving the lives of millions.

We look forward to welcoming you to this landmark event.

Yours faithfully,
CTAD Conference Management

Advancing Alzheimer's Disease Research: the CTAD Chinese Clinical Trials Center Initiative

The CTAD China Workshop, scheduled for September 6–7, 2025, marks the second convening of the **CTAD Chinese Clinical Trials Center Initiative**. This initiative was officially launched during its inaugural meeting on November 1, 2024, in Madrid, Spain, as part of the annual CTAD conference.

The first meeting served as a platform to introduce the initiative, fostering discussions on **perspectives, potential global collaborations, and the identification of opportunities and challenges** in clinical trial execution. The overarching goal of the initiative is to **strengthen the global capacity for conducting high-quality clinical trials, accelerating the development of therapeutic solutions for Alzheimer's Disease.**



CTAD Chinese Clinical Trials Initiative • First meeting • November 1, 2024

November 1, 2024 – Meeting Participants

Paul Aisen, MD, ATRI, University of Southern California (USC)
- San Diego (United States)

Sandrine Andrieu, MD, PhD, INSERM U 1295, IHU HealthAge,
Toulouse (France)

Piu Chan, MD, PhD, Xuanwu Hospital of Capital University,
Beijing Institute of Geriatrics (BIG, Beijing (China)

Qidong Chen, MD, PhD, Beijing Tiantan Hospital, Capital
Medical University, Beijing (China)

Yolanda Chen, Eli Lilly & Company, Shanghai (China)

Wei Chen, MD, PhD, Zhejiang University School of Medicine, Sir
Run Run Shaw Hospital, Beijing (China)

Qin Chen, MD, PhD, West China Hospital, Sichuan University,
Chengdu City (China)

Jeffrey Cummings, MD, PhD, University of Las Vegas
Nevada, Las Vegas (United States)

Linbi Dai, PhD, The First Affiliated Hospital of USTC, Hefei City,
Anhui Province (China)

Yifeng Du, MD, PhD, Shandong Provincial Hospital, 324, Jinan
City, Shandong Province (China)

Frank Jessen, MD, PhD, University of Cologne, Medical
Faculty, Cologne (Germany)

Tengfei Guo, PhD, Institute of Biomedical Engineering,
Peking University, Shenzhen, Guangdong (China)

Yanqing Han, MD, PhD, Shanxi Cardiovascular Hospital,
Taiyuan City, Shanxi Province (China)

Longfei Jia, MD, PhD, Xuanwu Hospital, Capital Medical
University, Xicheng District, Beijing (China)

Rena Li, MD, Beijing Institute of Brain Disorders, Capital
Medical University, Beijing (China)

Valerie Legrand, ICON plc, Paris (France)

Shen Lu, MD, PhD, Xiangya Hospital of Central South University,
Changsha City, Hunan Province (China)

Lefkos Middleton, MD, PhD, Imperial College London,
London (United Kingdom)

Xiaodong Pan, MD, PhD, Fujian Medical University Union
Hospital, Fuzhou City, Fujian Province (China)

Guoping Peng, MD, PhD, The First Affiliated Hospital, Zhejiang
University School of Medicine, Hangzhou City, Zhejiang Province
(China)

Yong Shen, PhD, The First Affiliated Hospital of USTC (Anhui
Provincial Hospital), Hefei City, Anhui Province (China)

Jiong Shi, MD, PhD, The First Affiliated Hospital of USTC (Anhui
Provincial Hospital), Hefei City, Anhui Province (China)

Yi Sui, MD, PhD, Shenyang First People's Hospital, Shenyang
City, Liaoning Province (China)

Li Sun, MD, PhD, The First Bethune Hospital of Jilin University,
Changchun City, Jilin Province (China)

Gilles Tamagnan, PhD, MITRO, Shanghai (China)

Huidong Tang, MD, PhD, Rui Jin Hospital, Huangpu District,
Shanghai (China)

Yi Tang, MD, PhD, Xuanwu Hospital, Capital Medical
University, Beijing (China)

Jacques Touchon, MD, PhD, Montpellier University Hospital,
Montpellier, (France)

Bruno Vellas, MD, PhD, IHU HealthAge, Toulouse (France)

Fei Wang, MD, PhD, Huangshan City People's Hospital,
Huangshan City, Anhui Province (China)

Bo Wang, MD, PhD, Shanghai Medical Innovation and
Development Foundation, - Hongkou District, Shanghai (China)

Gang Wang, MD, PhD, Renji Hospital affiliated Medical School
of Shanghai Jiao Tong University, Shanghai (China)

Huali Wang, MD, PhD, Chinese Institute for Brain Research,
Beijing (China)

Qiong Wang, MD, PhD, Institute on Aging and Brain Disorders
and Department of Neurology The First Affiliated Hospital of
USTC, Hefei City, Anhui Province (China)

Cuibai Wei, MD, Xuanwu Hospital, Capital Medical University,
Beijing (China)

Bengt Winblad, MD, PhD, Karolinska Institute, Stockholm
(Sweden)

Hui Wu, PhD, Jilin University, Changchun City, Jilin Province
(China)

Xiaohua Xiao, MD, PhD, Shenzhen Second People's Hospital/
First Affiliated Hospital of Shenzhen University, Shenzhen (China)

Jun Xu, MD, PhD, Beijing Tiantan Hospital, Capital Medical
University China National Clinical Research Center for
Neurological Diseases, Beijing (China)

Yun Xu, MD, PhD, Nanjing Drum Tower Hospital and Nanjing
University Medical School, Nanjing, Jiangsu (China)

Jin-Tai Yu, MD, PhD, Huashan Hospital, Fudan University,
Shanghai (China)

Zhentao Zhang, MD, PhD, Renmin Hospital of Wuhan
University, Wuhan City, Hubei Province (China)

Nan Zhang, MD, PhD, Tianjin Medical University General
Hospital, Tianjin (China)

Jiewen Zhang, MD, PhD, Henan Provincial People's Hospital,
Zhengzhou City, Henan Province (China)

Qinge Zhang, MD, PhD, Beijing Anding Hospital, Capital
Medical University, Xicheng District, Beijing (China)

Yingchun Zhang, MD, PhD, Zhejiang University School of
Medicine, Sir Run Run Shaw Hospital, Hangzhou, Zhejiang
(China)

Xinyu Zhao, MD, PhD, The First Affiliated Hospital of
Zhengzhou University, Medical School of Zhengzhou University,
Zhengzhou, Henan (China)

Kate Zhong, MD, CNS Innovation, Las Vegas (United States)



Unlock Premier Visibility and Strategic Engagement: CTAD25 China Workshop Partnership Opportunities

The Clinical Trials on Alzheimer's Disease (CTAD) Conference invites select organizations to partner with us for the CTAD25 China Workshop, a pivotal event shaping the future of Alzheimer's Disease (AD) research and drug development to be held on September 6-7, 2025 in Shanghai (China). By becoming a partner, your organization will solidify its position as a leader in the AD therapeutic landscape while connecting with top-tier stakeholders in clinical trials and innovation.

Join Us in Shaping the Future of Alzheimer's Disease Treatment

Your partnership will highlight your leadership in the AD space while fostering a collaborative environment for breakthrough innovations. Together, we can accelerate progress in the fight against Alzheimer's Disease.

Secure your partnership today and make your mark at CTAD25 China Workshop.



Why Partner with CTAD25 China Workshop?



High-Impact Visibility

Showcase your brand to a highly targeted audience of global decision-makers, researchers, and innovators in AD.



Strategic Networking

Build meaningful connections with industry leaders, researchers, and key influencers driving AD therapeutic advancements.



Thought Leadership

Align with CTAD's mission to advance groundbreaking pathways in Alzheimer's treatment and demonstrate your commitment to tackling one of the most critical health challenges of our time.



The Journal of Prevention of Alzheimer's Disease (JPAD) is the official journal of the CTAD Conference. This open access journal publishes reviews, original research articles and short reports to improve the knowledge in the field of Alzheimer's Disease.

JPAD publishes also the meeting abstracts from the Clinical Trial on Alzheimer Disease - CTAD's event.

The Journal of Prevention of Alzheimer's Disease is indexed in MEDLINE, SCIE (WoS), Scopus, and ranked in its categories in the first quartile (Q1) in both SCIE (WoS) and Scopus databases.

9.2 CiteScore
8.5 Impact Factor

Partnership Levels and Benefits



Platinum Level – €30,000 (excluding VAT)

Position your organization as a cornerstone of the workshop with premium benefits:

- 10 full conference registrations
- Exclusive access to a private meeting room for an investigator meeting, board meeting, or CTAD-related event
- A one-hour Satellite Symposium outside scientific hours
- Option to sponsor the opening cocktail reception
- Prominent logo placement on the CTAD China website, program materials, and conference signage, recognizing your pivotal role in AD research
- One-page insert in attendee bags
- Tabletop exhibit space to maximize visibility

Gold Level – €22,500 (excluding VAT)


Gain significant visibility and engagement opportunities:

- 5 full conference registrations
- A 30-minute breakfast Satellite Symposium on September 7, 2025
- Access to book a private meeting room for strategic discussions (additional cost applies)
- Logo placement on the CTAD China website, program materials, and conference signage
- One-page insert in attendee bags
- Tabletop exhibit space to enhance your brand's presence

Silver Level – €10,000 (excluding VAT)

Establish your presence within the AD research community:

- 3 full conference registrations
- Logo placement on the CTAD China website, program materials, and conference signage
- One-page insert in attendee bags
- Tabletop exhibit space



Contact

bene.clement@ant-congres.com
+33 6 10 25 38 96

WeChat

